JMP Securities Boosts DBV Technologies (NASDAQ:DBVT) Price Target to $15.00

DBV Technologies (NASDAQ:DBVT) had its target price upped by equities research analysts at JMP Securities from $10.00 to $15.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ target price points to a potential upside of 67.60% from the company’s previous close.

Separately, StockNews.com started coverage on DBV Technologies in a report on Thursday. They set a “hold” rating for the company.

DBV Technologies Price Performance

Shares of DBVT stock opened at $8.95 on Thursday. The company has a 50-day moving average of $6.37 and a two-hundred day moving average of $4.66. The firm has a market cap of $245.14 million, a PE ratio of -1.99 and a beta of -0.08. DBV Technologies has a 1-year low of $2.20 and a 1-year high of $9.89.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Friday, April 11th. The company reported ($1.10) earnings per share for the quarter. DBV Technologies had a negative net margin of 815.73% and a negative return on equity of 106.07%. The company had revenue of $0.51 million during the quarter. Sell-side analysts anticipate that DBV Technologies will post -7.05 EPS for the current fiscal year.

Hedge Funds Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC acquired a new stake in DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies at the end of the most recent quarter. Hedge funds and other institutional investors own 71.74% of the company’s stock.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.